U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06905587) titled 'Methylphenidate in Pediatric Brain Tumor Survivors with Cancer-related Fatigue' on Nov. 27, 2024.
Brief Summary: Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking.
The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD)...